Advanced Search


Study ID Status Title Patient Level Data
104505 Completed Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Study Listed on
104507 Completed Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Study Listed on
104510 Completed A Phase I, Dose Escalation, Open Label, Multicenter Study of Iodine-131 Anti-B1 Antibody for Intermediate and High Risk B Cell Chronic Lymphocytic Leukemia Study Listed on
104512 Completed Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients with Previously Treated Non Hodgkin’s Lymphoma With More Than 25% Bone Marrow Involvement Study Listed on
104514 Completed Phase II multicenter study of cyclophosphamide, vincristine, and prednisone (CVP) followed by Iodine-131 anti-B1 antibody for patients with untreated low-grade non-Hodgkin’s lymphoma (NHL). Study Listed on
104515 Completed Phase II a randomized study of iodine-131 Anti-b1 Antibody versus anti-b1 Antibody in chemotherapy-relapsed/refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL) Study Listed on
104517 Completed Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin’s Lymphoma Study Listed on
104540 Completed A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate adjuvanted vaccine in an elderly population aged over 65 years previously vaccinated in 2004 with the same candidate vaccine Study Listed on
104543 Completed A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic pharmacokinetics of GSK159802 administered once daily for 28 days in healthy male subjects.
104567 Completed Phase IIIb, multicentre study to assess safety & immunogenicity of GSK Biologicals’ combined DTPa/Hib (Infanrix/Hib) vaccine vs separate administration of DTPa (Infanrix) & Hib (Hiberix) vaccines in healthy infants 3,4,&5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites. Study Listed on
104574 Completed A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Study Listed on
104578 Completed A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer
104603 Completed : Phase I Study of SB-497115-GR – Single Oral Dose Study in Healthy Japanese Male Subjects –
104619 Completed A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Study Listed on
104631 Completed An open-label, randomized, five-period, period-balanced, crossover study to assess the effect of food and antacid on the pharmacokinetics of a single dose of SB-497115-GR (eltrombopag) in healthy volunteers
104648 Completed A study to evaluate the effect of repeat oral doses of lamotrigine on cardiac conduction as assessed by 12-Lead ECG as compared to placebo and single oral doses of moxifloxacin. Study Listed on
104703 (Primary study) Completed A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old Study Listed on
104727 (Booster - 15-24 mths) Completed Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a dose of Mencevax™ ACWY at 24-30 m in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC Study Listed on
104728 Completed RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II study to determine the safety and efficacy of Coulter Clone® 131Iodine-B1 radioimmunotherapy of advanced non-Hodgkin’s Lymphoma Study Listed on
104730 Completed A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727. Study Listed on
104731 Completed Multicenter, Phase II Dosimetry/Validation Study of 131Iodine–Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies Study Listed on
104733 Completed Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months Study Listed on
104745 Completed Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People age 18 or beyond Study Listed on
104756 Completed Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007 Study Listed on
104772 Completed Assess lot-to-lot consistency of GSK Biologicals' HPV-16/18 L1/AS04 vaccine following manufacturing adjustments administered intramuscularly according to a 0,1,6-mth schedule in healthy female subjects (18-25 y) Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.